PADMANEE SHARMA to Academic Medical Centers
This is a "connection" page, showing publications PADMANEE SHARMA has written about Academic Medical Centers.
Connection Strength
0.029
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.029